**D. Appendix 4. Detailed results of positive signals (FDR < 0.05; Specificity** ≥ **0.99) of disorders referred in main manuscript related to statins reported as ADR in Vigiaccess™ database and analyzed by a contrasted approach of Bayesian confidence propagation neural network (BCPNN) extended to the multiple comparison setting for active ingredients groups**

Interpretation of items: drug code: active ingredient reported; event effect: ADR reported; count: number of couples 'active ingredient-ADR' reported; expected count: couples 'active ingredient-ADR' expected; post.H0: posterior probability of null hypothesis; n11/E: ratio between the count observed and the count expected of the corresponding couple; drug margin: number of reports of a drug; event margin: number of reports of an event; FDR: false discovery rate; FNR: false negative rate; Se: Sensitivity(\* ≥ 0.20); Sp: Specificity.


*Rhabdomyolysis.*

